• microscope with slide

    Clinical Trials: New Developments in Dermatology

The UC Davis Department of Dermatology has several ongoing clinical trials. Click below to learn more.

1. Use of embrace device after cutaneous wound closure: a randomized evaluator blinded split wound comparative effectiveness trial

Indication: aesthetic dermatology
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

 

2. Comparison of cosmetic outcomes of straight line and W-plasty techniques for linear wound closure: a randomized evaluator blinded split wound comparative effectiveness trial

Indication: aesthetic dermatology
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

 

3. Aesthetic outcome of simple cuticular suture distance (2mm vs 5mm) from wound edge on the closure of linear wounds on the head and neck: a randomized evaluator blinded split wound comparative effective trial

Indication: aesthetic dermatology
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

 

4. Aesthetic outcome of complex linear closure vs second intention healing for cutaneous surgical procedures performed below the knee: a randomized, blind control trial

Indication: aesthetic dermatology
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

 

5. Aesthetic outcome of electrodesiccation and curettage vs excision with complex linear closure for low risk lesions on the trunk and extremities: a randomized, blind control trial

Indication: aesthetic dermatology
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

 

6. Antibiotic adherence practices in dermatologic surgery: a multicenter prospective cohort study

Indication: aesthetic dermatology
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata

Primary Investigator: Emanual Maverakis, MD
Contact: Monica Tran, (916) 734-1509

1. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Primary Investigator: Emanual Maverakis, MD
Contact: Lauren Downing, (916) 734-6550

 

2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 Co-Administered with Background Medicated Topical Therapy in Adolescent Participants 12 to <18 Years of Age with Moderate to Severe Atopic Dermatitis

Primary Investigator: Smita Awasthi, MD
Contact: Monica Tran, (916) 734-1509

 

3. Registry for the Study of Atopic Dermatitis Morphologic Phenotypes

Indication: Atopic Dermatitis in Children
Primary Investigator: Smita Awasthi, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • Pediatric patient < 17.7 years of age at time of enrollment
  • Clinical diagnosis of atopic dermatitis

 

4. Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

Indication: Seborrheic Dermatitis
Primary Investigator: Nasim Fazel, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • Age: 18 or above
  • Seborrheic Dermatitis on the Face

1. The Effect of an Oral Herbal Combination Formulation on Hair Growth in Women with Self-Perceived Hair Loss

Indication: Hair Growth, Supplements
Primary Investigator: Raja Sivamani, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • 18 years of age or older
  • Women with self-perceived hair loss as confirmed by the investigator

 

2. Genetic aberrations driving cutaneous disease

Indication: Genetics and cutaneous disease
Primary Investigator: Maija Kiuru, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • Subjects with active cutaneous, hair or nail disease (*this is something that must be confirmed by a dermatologist. We get those subjects from UCD dermatologists)
  • 18 years of age or older

1. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa

Primary Investigator: Emanual Maverakis, MD
Contact: Monica Tran, (916) 734-1509

1. Effect of pre-operative consultation on patient anxiety and satisfaction following first-time Mohs micrographic surgery

Indication: Mohs surgery
Primary Investigator: Daniel Eisen, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria: Current or past patient of primary investigator

1. A pilot study of transcriptional mechanisms underlying repigmentation of graying hair following cranial radiation treatment

Indication: Melanocytic nevi, moles
Primary Investigator: Maija Kiuru, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • 18 years of age or older
  • Those who will receive or have received cranial radiation
  • Partially or completely gray hair
  • Willing to obtain biopsies of scalp

 

2. Genetic basis of melanocytic nevi
Indication: Melanocytic nevi, moles
Primary Investigator: Maija Kiuru, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • Subjects with melanocytic nevi
  • 18 years of age or older

1. A phase 2B randomized, double-blind, placebo-controlled, mulitcenter, dose-ranging study to evaluate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 AND PF-06700841 in subjects with active non-segmental vitiligo.

Indication: Vitiligo
Primary Investigator: Victor Huang, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • Age: 18-65
  • Vitiligo w/ BSA involvement 4%-50%
  • BSA of at least 0.25% involvement on the face

1. Dysbiosis of the Gut Microbiome in Individuals with Type 2 Diabetes, Psoriasis, Essential Hypertension, or Hidradenitis Suppurativa and Correlation with the Blood Lipidome Profile

Indication: Gut Dysbiosis
Primary Investigator: Raja Sivamani, MD
Contact: Iryna Rybak, (916) 734-6556
Criteria:

  • Patients diagnosed with psoriasis
  • Patients diagnosed with hidradenitis suppurativa with a Hurley score of at least 2
  • Patients diagnosed with type 2 diabetes
  • Patients diagnosed with essential hypertension
  • 18 years of age or older

 

2. The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome (CLOSED)

Indication: Skin Wrinkles, Nutrition
Primary Investigator: Raja Sivamani, MD
Contact: Iryna Rybak, (916) 734-6556

 

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

Primary Investigator: Emanual Maverakis, MD
Contact: Lauren Downing, (916) 551-2635
Participant Criteria: